For all you non-diabetics reading my blog, let me explain - your pancreas internally, automatically produces insulin for you when you eat meals or drink beverages, etc. however, a diabetic, like myself, has to manually give themselves insulin. The problem is that we often don't know exactly how much or how little to give, how early or how late we should give it to when we eat, etc.
My battle with insulin goes back to before I can even remember. Because insulin takes so long to get into my system (because I manually give it to myself through a pump), this causes my blood sugars to fluctuate... constantly.
Now that faster-acting insulin has come out, I'm excited to try it out ASAP! To learn more about this insulin, read below!
New, faster-acting insulin from Novo Nordisk improves blood glucose levels in studies
04 February 2016
Results of two clinical trials into the effects of a fasting-acting version of NovoRapid have been unveiled at the 76th annual Scientific Sessions of the American Diabetes Association (ADA).
The new insulin was tested in people with type 1 diabetes in one of the clinical trials and tested in people with type 2 diabetes in the other of the trials. Within both trials, the new faster-acting insulin aspart was compared with the standard insulin aspart that is sold as NovoRapid.
Results of the trial involving patients with type 1 diabetes (ONSET 1 trial) showed that the new, faster-acting insulin aspart reduced HbA1c levels by 1.7 mmol/mol (0.15%) compared with standard insulin aspart. The study also showed a reduction in blood glucose levels for the faster-acting insulin of 1.2% mmol/l two hours after eating and 0.7 mmol/l one hour after eating, compared to standard insulin aspart.
The results of the trial involving patients with type 2 diabetes (ONSET 2 trial) showed that the new, fasting acting insulin aspart resulted in a reduction in blood glucose levels of 0.6 mmol/l one hour after eating compared to standard insulin aspart.
In type 2 diabetes, the faster-acting insulin did not show a significant reduction in blood glucose levels two hours after eating or of a reduction in HbA1c levels. This is not surprising, however, as people with type 2 diabetes are able to produce significant quantities of their pancreas’ own insulin, which may have outweighed the effects of the faster insulin.
The study reported no significant difference in the rates of hypoglycemia or severe hypoglycemia between the faster-acting insulin aspart and the standard insulin aspart in either of the trials.
Professor David Russell-Jones primary investigator for the ONSET 1 trial, stated: "Improving [post-meal plasma glucose] control is important in achieving HbA1c targets for patients with type 1 or type 2 diabetes. Poor control of [post-meal plasma glucose] can often result in post-meal hyperglycaemia, which can have a wide-range of negative effects on patients".
The new insulin was tested in people with type 1 diabetes in one of the clinical trials and tested in people with type 2 diabetes in the other of the trials. Within both trials, the new faster-acting insulin aspart was compared with the standard insulin aspart that is sold as NovoRapid.
Results of the trial involving patients with type 1 diabetes (ONSET 1 trial) showed that the new, faster-acting insulin aspart reduced HbA1c levels by 1.7 mmol/mol (0.15%) compared with standard insulin aspart. The study also showed a reduction in blood glucose levels for the faster-acting insulin of 1.2% mmol/l two hours after eating and 0.7 mmol/l one hour after eating, compared to standard insulin aspart.
The results of the trial involving patients with type 2 diabetes (ONSET 2 trial) showed that the new, fasting acting insulin aspart resulted in a reduction in blood glucose levels of 0.6 mmol/l one hour after eating compared to standard insulin aspart.
In type 2 diabetes, the faster-acting insulin did not show a significant reduction in blood glucose levels two hours after eating or of a reduction in HbA1c levels. This is not surprising, however, as people with type 2 diabetes are able to produce significant quantities of their pancreas’ own insulin, which may have outweighed the effects of the faster insulin.
The study reported no significant difference in the rates of hypoglycemia or severe hypoglycemia between the faster-acting insulin aspart and the standard insulin aspart in either of the trials.
Professor David Russell-Jones primary investigator for the ONSET 1 trial, stated: "Improving [post-meal plasma glucose] control is important in achieving HbA1c targets for patients with type 1 or type 2 diabetes. Poor control of [post-meal plasma glucose] can often result in post-meal hyperglycaemia, which can have a wide-range of negative effects on patients".
No comments:
Post a Comment